Nutritionals feed Abbott
This article was originally published in The Tan Sheet
Nutritional sales grew 11 percent in the fourth quarter to $1.28 billion globally, with U.S. revenues climbing nearly 7 percent driven by the launch of infant formula Similac Advanced EarlyShield and continued sales of Glucerna and Ensure. International nutrition sales rose 15 percent, the Abbott Park, Ill.-based firm said Jan. 21. To address increased demand in Asia, where consumers are shaken by the contaminated formula scandal that rocked China in 2008, Abbott will open a manufacturing facility in Singapore this quarter, Investor Relations VP John Thomas said during a same-day earnings call. He also said the firm expects its planned acquisition of Advanced Medical Optics to grow its market share more than $4 billion globally with help from sales of the Tecnis multifocal intraocular lens FDA approved Jan. 16 (1"The Tan Sheet" Jan. 19, 2009, p. 17). Abbott's net sales in the quarter advanced 10.1 percent to $8 billion and for the year revenues grew 13.9 percent to $29.5 billion
You may also be interested in...
Abbott Nutrition's innovative packaging for its Similac line of infant formulas shows the company empathizes with consumer's interests and needs, according to a leading industrial designer
Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers
MagGenome, an Indian biotech which develops magnetic nanoparticle-based products for therapeutics and molecular diagnostics, is in the early research stage for a nanoparticle-based adjuvant for vaccines. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the enabling environment being created in India for cell and gene therapies, among other topics, in this wide-ranging audio interview.